[Tirzepatide in real-world clinical practice: changes in body composition and muscle function in patients with obesity]
{{output}}
Introduction: obesity is a chronic and relapsing disease. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated weight loss exceeding 20 % at higher doses. However, real-world data remain limited, particularly rega... ...
